key: cord-0979803-691ybkan
authors: Pathak, Lekhika; Gayan, Sukanya; Pal, Bidisha; Talukdar, Joyeeta; Bhuyan, Seema; Sandhya, Sorra; Yeger, Herman; Baishya, Debabrat; Das, Bikul
title: Corona virus activates a stem cell mediated defense mechanism that accelerates activation of dormant tuberculosis: implications for the COVID-19 pandemic
date: 2020-05-06
journal: bioRxiv
DOI: 10.1101/2020.05.06.077883
sha: c2528dbf78fd0be58713baf8cf71fc7abc92414f
doc_id: 979803
cord_uid: 691ybkan

We postulate that similar to bacteria, adult stem cells may also exhibit altruistic defense mechanism to protect their niche. Here, we provide preliminary data on the altruistic stem cell (ASC) based defense against a mouse corona virus; MHV-1 infection. In a mouse model of mesenchymal stem cell (MSC) mediated M. tuberculosis (Mtb) dormancy, MHV-1 infection in the lung exhibited 20 fold lower viral loads than the healthy control mice, suggesting the potential enhancement of an anti-MHV-1 defense by Mtb. This defense involved the in vivo expansion and reprogramming of CD271+ MSCs in the lung to ASC phenotype characterized by activation of genes involved in the HIF-2alpha stemness pathway. The conditioned media of the ASCs exhibited direct anti-viral activity in an in vitro model of MHV-1 induced toxicity to type II alveolar epithelial cells. MHV-1 infected Mtb harboring group versus MHV-1 alone group exhibited an 8-fold (p<0.02; n=4) higher ASC reprogramming and 5-fold (p<0.001; n=3, student t test) higher anti-viral activity. However, ASCs facilitated intracellular replication and extracellular release of Mtb. Thus, our data suggest that MSCs exert an innate defense against MHV-1 by activating the ASC defense mechanism, which might be exploited by dormant Mtb to undergo reactivation. Hence, our findings may provide a novel anti-viral defense mechanism against novel corona virus SARS-Cov2, which could be further utilized to develop vaccine against COVID19. Our findings also predict a potential increase of tuberculosis in post-COVID19 era.

The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) mediated corona virus disease 2019 (COVID-19) pandemic demonstrates the ability of an emerging virus to create chaos in our modern health care system and a severe strain on the global economics. In the long term, post-pandemic, the SARS-CoV-2 might activate dormant bacterial infections. As per prior history, tuberculosis is one of the key bacterial infections affected by viral pandemics (1-5).

Strikingly, one quarter of the world population is already infected with dormant tuberculosis (TB) (https://www.who.int/news-room/fact-sheets/detail/tuberculosis). If SARS-CoV-2 infects these dormant TB populations, it may cause severe impact in global health and economics by causing both COVID19 and dormant TB reactivation. Thus, there is an urgent need to study the association of COVID19 with dormant TB reactivation to avoid a later global TB pandemic. Viral infection such as the influenza virus or SARS-Cov-1 is known to cause transient immune suppression that leads to reactivation of dormant bacterial infection (6) (7) 4) . In 1918, the Spanish flu pandemic led to the rise of pulmonary TB incidence (2, 8) . Influenza in patients with TB had the highest death rate (8) (9) . In the year 2009 during the influenza A (H1N1) pandemic, a worse prognosis of influenza was observed in patients with TB or MDR/TB (10-11). Interestingly,

patients were reported to develop pulmonary TB (PTB) (5, 4) . Using a mouse model, an earlier study showed that influenza A virus cause rapid development of PTB lesions (12) and increases the mycobacterium load in liver (13) . Another mouse models of Influenza A virus and Mtb coinfection led to enhanced Mtb growth by a type-I IFN signaling pathway (6) . However, severe inflammation in the lung is a common outcome of corona virus infection (14), a symptom which is also commonly observed in TB patients (15) . Thus, it is possible that corona virus infection causing inflammation may also lead to reactivate dormant Mtb in the lung, which has not yet been studied.

We have been investigating TB dormancy in the adult stem cell niches (16) (17) (18) . These stem cells reside in the bone marrow (BM) niche (19) and in the area of inflammation (20) . We have identified a rare fraction of cells in BM, the CD271+BM-mesenchymal stem cells (CD271+BM-MSCs) as the potential niche for dormant Mtb in both mice and humans (17) . In this stem cell niche, Mtb remains dormant, maintaining reactivation potential. Importantly, we have developed a mouse model of stem cell mediated Mtb dormancy (figure 3, (17) . Briefly, streptomycin dependent mutant 18b strain infected mice exhibit lung infection following 3 weeks of streptomycin treatment. These mice develop granulomas, and also acquire humoral immunity against the bacteria. Following streptomycin starvation for 6 months, the bacteria acquire a nonreplicating status. Mostly, these bacteria can be detected in the CD271+MSCs of BM, but a few are also present in the CD271+MSCs of lung (17) . Furthermore, Mtb harboring CD271+ MSCs reside in the hypoxic niche of BM (18) . Notably, in this model, the presence of Mtb-CFUs in the non-CD271+MSC compartment of lung can be utilized as a sign of Mtb reactivation. Thus, the model can be used to study the stem cell mediated Mtb reactivation. Using this mouse model of stem cell mediated Mtb dormancy; we sought to find out if corona virus can reactivate dormant Mtb (dMtb). We are using a mouse corona virus strain; murine hepatitis virus strain-1 (MHV-1), that represents clinically relevant model of human infecting corona virus strain; SARS-CoV-1 (21) (22) (23) . MHV-1 causes acute lung inflammation by inducing acute respiratory infection (ARI) within 2-4 days in C57BL/6 mice by increasing viral load. 5 Animals exhibit an elevated level of pro-inflammatory cytokines such as TNF-alpha during 2-14 days post-infection (21, 24) and then fully recover (21) . Importantly, in vitro study demonstrated that MHV-1 can infect type II alveolar epithelial (ATII) cells (25) . Therefore, ATII cells could be utilized in the MHV-1 model to study if these cells can exert the putative altruistic stem cell (ASC) based defense mechanism against the virus.

Here, we demonstrate that MHV-1 infection activates an innate defense mechanism of ASCs that we previously identified in embryonic stem cells (ESCs) (26) by enhancing Mtb reactivation.

Our results suggest that MHV-1 activates a niche defense mechanism in the stem cells harboring Mtb, which leads to a reduction in the viral load by inducing a mycobacterium load in the lung.

Interestingly, our invitro results indicate that, although this ASC mediated defense mechanism reactivates Mtb, it also increases the survival percentage of neighboring lung epithelial cells.

Thus, this niche defense mechanism could be further explored to develop therapeutics to target corona virus.

Mycobacterium strain and growth condition: All the necessary experimental procedures were approved and undertaken inside BSC-class II facility in accordance with guidelines of "Institutional Bio-safety Committee" of KaviKrishna Laboratory. Streptomycin-auxotrophic mutant Mtb strain18b (gifted by Prof. Stewart T. Cole, Ecole Polytechinque Federale de Lausanne, Lausanne, Switzerland) was cultured in BBL Middlebrook 7H9 broth with glycerol (BD Bioscience, #221832) along with 50 µg/ml of streptomycin sulfate. It was maintained at 37˚C and 5% CO2 with occasional shaking until the mid-logarithmic phase was reached, OD approximating to 1. Laboratory. The 6-8-week-old C57BL/6 female mice were obtained from National Institution of Nutrition, Hyderabad, India and were maintained in the animal house of Gauhati University at pathogen free condition as previously described (17) . The mice model of Mtb dormancy was developed in 6 months as previously described (17) . Briefly, streptomycin-auxotrophic mutant Mtb strain18b cell suspension was prepared in phosphate buffered saline (PBS)-Tween 80 (0.05%), sonicated for 15 seconds, and intravenously injected with 2x10 6 CFUs per mouse.

Initially for 3 weeks streptomycin was administered (3mg/mouse in 200 µl of normal saline) daily for establishing infection. Then, mice were observed for 6 months without any streptomycin treatment to establish bacterial dormancy. Following 6 months of streptomycin starvation, lung tissue were dissociated; CD271+/CD45-MSCs and non CD271+ cells were isolated by magnetic sorting as previously explained (18) . The magnetically sorted CD271+MSCs and non CD271+ cells were subjected to Mtb-CFU assay. Consistent with our previous findings (17) , a small number of Mtb-CFUs (38±10 Mtb-CFU/lung) were obtained only in CD271+MSCs. Thus, mice model of Mtb dormancy was developed. Then, streptomycin was injected intraperitoneally (3mg/mouse in 200 µl of normal saline) daily for 3 weeks (17) with or without MHV-1 infection (21, 23) to develop mice model of reactivation. In a separate experiment, streptomycin treated mice were also treated with immunosuppressive agents dexamethasone (0.08mg/day, 6 times a week) or amino guanidine (2.5% wt/vol in drinking water) to cause dMtb reactivation (27) . The treated mice were observed for stipulated period of time, and then sacrificed to collect lung tissues. The Mtb-CFU of lung was evaluated for Mtb reactivation.

Isolation and culture of CD271+MSCs: The mice lung tissues were dissociated using collagenase/lipase and then, cells were subjected to magnetic sorting to isolate CD271+MSCs as explained previously (17) (18) . Briefly, CD45-cells were magnetically sorted using Mtb-CFU assay, cells were cultured for 4-8 hours in serum free media without any growth factor.

For cytoprotective assay, cells were isolated on day 8 following infection and cultured (1x10^7 cells/ml) in Dulbecco's modified Eagle's medium (DMEM)/F12 media without serum for 24 hours to obtain the conditioned media.

This was carried out as previously described (17) (18) .

For the whole lung Mtb-CFU, the lung tissue were aseptically removed from sacrificed mice and homogenized in PBS with 0.05% Tween 80, then subjected to CFU assay (18) . For the Mtb-CFU assay of immunomagnetically sorted cells, cells were isolated by dissociating lung tissue using Collagenase/Lipase (17) . The pellet was lysed with 1 ml of 0.1% Triton X-100 for 15 min, vortexed for 30 seconds, and serial 10-fold dilution was prepared in Middlebrook 7H9 broth. The diluted whole lung or cell lysate were then separately plated on Middlebrook 7H10 agar plates (BD Bioscience, #295964) along with streptomycin (50µg/ml) for the growth of m18b strain. 8 The agar plates were incubated for 3-4 weeks at 37 o C and 5% CO2 and CFUs were counted.

CFUs were plotted as the means of log10 CFUs per lung or per 10 7 cells. qPCR assay: To isolate the mRNA from bacterial infected CD271+MSCs, we used the µMACS TM technology (Miltenyi Biotec, Bergisch-Gladbach, Germany) as described previously (17) . Briefly, the mRNA is isolated in a magnetic column using super paramagnetic Oligo (dT)

Microbeads which target the poly RNA tail of mammalian RNA. The mRNA gets attached to the magnetic column, whereas the bacterial and stem cell DNA remained in the passed-through lysate. Then, the mRNA was converted to cDNA in a heated magnetic bar as per manufacture instruction and cDNA was subjected to qPCR analysis using the TaqMan Gene expression assay Biotech, Bergisch-Gladbach, Germany). RNA quantification was done using the ΔΔ Ct method by using the SDS software, version 2. 

Culture Collection (ATCC) and cultured inside the BSC-class II facility at KaviKrishna Laboratory in accordance with approval of "Institutional Bio-safety Committee" and "Institutional Ethics Committee" of KaviKrishna Laboratory. The animal protocol was approved by the "Institutional Ethics Committee" of KaviKrishna Laboratory and Gauhati University, Guwahati. MHV-1 was propagated on L2 (ATCC HCCL-149) cells, purified by sucrose gradient centrifugation and titrated by end point dilution assay on L2 cells to determine titer of the viral 9 stock as previously described (28) . Mice (C57BL/6 mice previously infected with the mutant 18b

Mtb strain followed by 6 months of streptomycin starvation, or control group (25-26 weeks old healthy mice) were intranasally infected with 5000 PFUs of MHV-1 per mouse (21, 23) . Briefly, animals were anesthetized with ketamine intraperitoneally and then 50 µl of MHV-1 in PBS was administered intranasally; this dose is known to cause ARI in this strain of mice (22,24).

Evaluation of lung infection was done by viral load study and measurement of TNF-alpha on day 0 and 6 as described (21, 24) .

This assay was performed as previously described (28) . In specific time period, animals were euthanized, and the whole lungs were harvested. The lung tissue was homogenized as described (17) , and the supernatant was stored at -80°C prior to further analysis. One day prior to the formation of the PFU assay, L2 cells were seeded so that the cell density could reach confluence on the day of PFU assay. The serial dilution of lung homogenate derived supernatant was loaded on the L2 monolayer cells and incubated for one hour at 37˚C. The inoculum was removed, and it was over layered with methylcellulose media and incubated for 48 hr at 37 ˚C. The plaques were then counted and the virus titer was calculated using the following formula: titer (PFU/ml) = [(number of plaques/well)/(volume of inoculum/well)] x dilution factor.

Enzyme Linked Immunosorbent Assay (ELISA) for TNF-alpha evaluation: This was done by using an Elisa Kit (#MTA00B) of R&D Systems (Minneapolis, MN) as described previously (26) . Briefly, whole lungs were harvested and homogenized in DMEM/F12 medium supplemented with protease inhibitor mix (Sigma Aldrich). Lung homogenates were centrifuged, and 50 μl of supernatant was added to the wells of the ELISA plate, covered and incubated at room temperature for 2 hours. Each well was aspirated and washed for five times as mentioned 10 in the kit. 100 μL of Mouse TNF-alpha conjugate to horseradish peroxidase was added to each well and covered with an adhesive strip. It was then incubated for 2 hours at room temperature and then aspirated and washed. The plates were developed for 30 minutes using 100 μL of tetramethylbenzidine plus hydroegen peroxide. Plates were read at 450 nm using iMark™ Microplate Absorbance Reader (Biorad, Gurgaon, India).

The type II alveolar epithelial (ATII) cells of healthy C57BL/6 mice were first isolated as previously described (25) by isolating CD45-, and EPCAM+ cells using immunomagnetic sorting (29) . The isolated cells were cultured in the fibronectin coated 6-well plates (2x10^5 cells/well) using DMEM/F12 and 10% FBS with penicillin/streptomycin antibiotics. The cells were infected with MHV-1 with a MOI of 1:5 as described (25) and then treated for 48 hours with the CM obtained from the lung CD271+MSCs collected from the three groups (dMtb alone, MHV-1 alone and the dMtbMHV-1 group). The conditioned media (CM) was collected from in vivo CD271+ MSCs by a previously described method (26) , where the isolated CD271+MSCs (1x10^7 cells/ml) were cultured in vitro for 24 hours, and then CM was filtered through a 0.2 micron filter. The filtered CM was added to ATII cells. After 48 hours of growth, cytoprotection was measured by the reduction in viral load (viral plaque assay), and cell survival (trypan blue assay). Trypan blue assay was done as previously described (26) . Dunnett's post-hoc test. Data are expressed as means ± SEM; *P < 0.05, **P < 0.001, ***P < 0.0001.

We reasoned that MHV-1 infection increases the Mtb-CFU level in the mice lungs containing dMtb harboring MSC, and thus, could reactivate pulmonary TB. To test this hypothesis, MHV-1 (5x10^3 PFU) was intranasally administered to C57BL/6 mice (n=25) (21, 23) , having lung CD271+ MSCs, that contain streptomycin-dependent mutant Mtb strain of 18b in non-replicating dormant state for 6 months (17, 30) . Simultaneously, mice were also injected with streptomycin as the mutant 18b strain requires the antibiotic to replicate (30) . Study was ended after three weeks, because (i) three weeks of streptomycin is sufficient to establish lung infection (17) were sacrificed at stipulated time, lungs obtained, and the viral titers as well as Mtb-CFUs in the lung tissues were evaluated ( Figure 1B-C) . We also measured the TNF-alpha in the animals' blood on day-2 of MHV-1 infection to confirm MHV-1 induced immune response (21) . First, we evaluated the viral infection in the mice as shown in Figure 1B . MHV-1 infected healthy mice were used as the control. In this control group, streptomycin was also added to find out if addition of streptomycin can affect the viral load. MHV-1 infection in the control group led to an increase in viral titers in the mouse lung for the first 4 days, and then gradually decreased within next two weeks, which is consistent with the previous result of C57BL/6 mice (23). MHV-1 infected mice with dMtb (henceforth, dMtbMHV-1 group) showed an increase in viral load for the first 4 days similar to control, but then rapidly subsided at the end of two-weeks, where the viral load was 20-fold less than control group (p<0.004; Figure 1B) . The TNF-alpha levels in both the groups were increased by 3-4 fold (p<0.03; n=4) on day-2 (dMtb-32.5 ±11.4 vs7.3±4.5pg/ml; dMtbMHV-1-36.5 ±14.7 vs9.5 ± 3.6pg/ml). These data suggest that MHV-1 infection activated viral replication, and associated immune response in both groups, although, viral load decreased in Mtb-infected versus non-infected mice.

Second, we evaluated Mtb-CFUs in the lungs of dMtb alone versus dMtbMHV-1 group. Both the groups (n=10 mice in each group) received daily streptomycin treatment for mutant strain to replicate. By 8 days of infection Mtb-CFUs was 6-7 fold greater than the Mtb-CFU prior to the start of the infection in both the groups (p<0.0001, Figure 1C ). Then, between days-8 and 20 of post-infection, Mtb-CFUs increased by 110-fold (p<0.0001) in the dMtbMHV-1 group but, decreased by 2.1-fold (p<0.004) in the dMtb alone group. These results indicate that MHV-1 infection not only initiated but also sustained the Mtb reactivation process following streptomycin treatment. In contrast, Mtb reactivation did not occur in the dMtb alone group as the streptomycin treatment alone failed to increase Mtb-CFUs even after three weeks of treatment. Importantly, we found 630 fold increases in Mtb-CFU between days 0-20 in the dMtbMHV-1 group, which is equivalent to 1000 fold increase in Mtb-CFU in a dexamethasone and aminoguanidine induced Mtb reactivation model (27) .

Therefore, next we compared the MHV-1 induced reactivation of the dMtb with dexamethasone, or aminoguanidine. These have been found to reactivate dMtb in a drug-induced Cornell model by suppressing the immune system (27) . To compare the reactivation of MHV-1 versus these immunosuppressive agents, dMtb harboring mice were treated with either of these two drugs and streptomycin daily for a month, then the lung Mtb-CFUs were quantified. Next, the Mtb-CFU of these two drugs treated mice with the Mtb-CFU obtained from one-month post-MHV-1 infected mice were compared. We found that Mtb-CFUs increased by only 3-4-fold (p=0.06; n=4) 13 following either dexamethasone or aminoguanidine treatment, which was 400-fold lower than the MHV-1 infection group (p<0.00001, n=4; Figure 1D ). Thus, MHV-1 infection was superior to dexamethasone or aminoguanidine to induce reactivation in our model of dMtb. Our results also indicate that mechanisms other than immunosuppression may underlie MHV-1 infection mediated disease reactivation.

In this mouse model of Mtb dormancy, dMtb remains dormant in CD271+MSCs of bone marrow and lung. We hypothesized that during dMtb reactivation, the bacteria transfer from MSCs to non-MSC compartments in the lung (17) . Thus, we analyzed the lung CD271+MSCs for intracellular Mtb replication and release into the extracellular space. Lung CD271+MSCs were obtained by immunomagnetic sorting after a stipulated time period of MHV-1 infection, Viable cell count was obtained by trypan blue to evaluate expansion of these cells. The dMtb group served as a control. We also studied possible CD271+MSCs expansion in healthy mice infected with MHV-1 to evaluate a potential effect of this virus on MSCs of lung. Next, the sorted cells were cultured in serum-free media for 8 hours to evaluate both the intracellular and the extracellular release of Mtb by measuring Mtb-CFUs in the cell pellet and supernatant respectively. We found that the dMtbMHV-1 group showed a transient 12-fold (p<0.001) expansion of CD271+MSCs between day-0 and 8. Strikingly, we also found that MHV-1 infection alone group exhibited expansion of CD271+MSCs. However, the expansion was 6-fold lower than the dMtbMHV-1 group; the dMtb alone group showed no expansion of the MSCs ( Figure 2B) . Notably, in the dMtbMHV-1 group, along with MSC expansion, there was a corresponding 27-fold (p<0.0001) increase in the number of intracellular Mtb-CFUs ( Figure 2C ). 14 During this period supernatant of dMtbMHV-1 group did not exhibit marked increase in extracellular Mtb-CFUs compared to dMtb control ( Figure 2D ). However, in the next four days i.e. between day-8 and 12, supernatant showed a 40-fold increase of Mtb-CFU (p<0.0032; Figure   2D ). Thus, Mtb-transfer from CD271+ MSCs to non-CD271+MSC compartment probably occurred between the day-8 and 12, when the supernatant showed a sharp increase in Mtb-CFUs. 

The MHV-1 infection induced transient expansion of lung CD271+MSCs in both Mtb harboring and healthy animal group encouraged us to study the underlying molecular mechanism of expansion. We considered that MHV-1 infection may activate an altruistic stem cell (ASC) based innate defense mechanism that we previously identified in human embryonic stem cells (hESCs) (26) , and also in mesenchymal stem cells (MSCs) (18) . Briefly, when a clone of stem cells such as hESCs cell colony is threatened by hypoxia/oxidative stress induced differentiation/apoptosis, a few of these cells reprogram to an "enhanced stemness" phenotype. This phenotype is characterized by distinct gene expression associated with HIF-2alpha stemness pathway (26, 31) , and rapid expansion of the reprogrammed cells. These cells continue to maintain enhanced stemness phenotype for the next two weeks, and then activate p53 to undergo 15 differentiation/apoptosis. During the expansion period, these cells exhibit altruistic behaviors by secreting cytoprotective agents such as glutathione that enhance the fitness of the rest of the hES cells. Thus, we identified stem cells with the "enhanced stemness" reprogramming as altruistic Stem Cells (ASCs) (26) , and described these cells as "intermediate" cell type in Waddington's epigenetic landscape (32) ( Figure 3A ) (33) . Indeed, transient cells having ES cell like phenotype has been identified in mice and human, including our findings (34) using defined criteria (35) ( Figure 3B ), suggesting the clinical significance of ASCs. We speculate that this ASC reprogramming may function as a putative innate defense system against invading pathogens that threaten the integrity of the stem cells residing in their niches (35) . Thus, our findings of MHV-1 mediated transient expansion of CD271+MSCs may be part of the ASC defense mechanism against the virus. Indeed, the day-8 CD271+MSCs of MHV-1 infected healthy mice not only showed expansion ( Figure 2B ), but when subjected to real-time PCR gene expression study ( Figure 3C ), these cells also exhibited marked alteration of genes associated with enhanced stemness phenotype (HIF-1alpha, HIF-2alpha, Sox2, Oct4, Nanog, ABCG2, MDM2, GCL, p53, and p21) ( Figure 3D ). We further characterized the stemness of these CD271+MSCs and indeed, they expressed the MSC markers on day 8; CD73, CD74, and Sca-1 whereas CD45 was not expressed ( Figure 3D ). Demonstration of the increased up-regulation of p53-upstream genes bax, p21 and PUMA, and down-regulation of HIF-2alpha on day-20 ( Figure 3E) , further confirm the ASC reprogramming. We also noted that the expression of Sca-1 was down regulated in these cells on day 20 ( Figure 3E) , suggesting differentiation. Interestingly, in the dMtbMHV-1 group, the several ASC reprogramming related gene (Oct4, GCL and ABCG2) expression was increased by 2-3-fold compared to MHV-1 infection alone group ( Figure 3D) . Thus, these findings suggest that MHV-1 infection led to ASC reprogramming of CD271+MSCs, and this reprogramming was also seen in the dMtb harboring mice, when infected with MHV-1.

Activation of p53 upstream genes on day-20 also indicated the activation of the proposed ASC based innate defense mechanism in the infected CD271+MSCs against MHV-1.

We confirmed this ASC based defense against MHV-1 mediated viral load and cellular toxicity in an in vitro viral infection assay ( Figure 4A ). We demonstrated that the conditioned media (CM) of CD271+MSCs on day-8 were capable of exhibiting significant 2-3-fold 

The COVID-19 caused by SARS-COV2, has created a global pandemic associated with substantial mortality and morbidity. Notably, a significant number of infected individuals have recovered. However, evidence for a possible host defense or anti-viral mechanism against the virus has not yet been identified. Currently, there are no approved drugs or vaccines to treat COVID-19. Here, we demonstrate a mouse corona virus model with a potential ASC based defense mechanism activated by dMtb loaded lung CD271+MSCs against the virus. As per recent data from some surveys and reports, it has been seen that countries which do not have a policy of universal Bacille Calmette Guerin (BCG) vaccination have experienced higher mortality related to COVID-19 (36) (37) . Interestingly, BCG is closely related to Mtb which enhanced ASC based defense mechanism of CD271+MSCs to fight against MHV-1 infection. Thus, our results described here could provide a novel explanation of BCG mediated host defense or anti-viral mechanism against SARS-CoV2 that could be further utilized to design a drug or vaccine against the virus.

In a hostile microenvironment, microorganisms like bacteria activate a unique defense mechanism (38) , which can be explained as a charitable deed that help the neighbors to survive unfavorable conditions. We have identified a similar altruistic stem cell defense system in hESc, wherein a subset of these cells, (SSEA3+/ABCG2+), acquire an enhanced stemness state that enable these cells to secrete antioxidants and growth factors in the hostile microenvironment of oxidative stress. This altruistic act protects the rest of the population from oxidative stress induced apoptosis and differentiation (26) . The enhanced stemness state is associated with an increased expression of Oct-4 and Nanog governed by an altered and transient state of the p53/MDM2 oscillation system. After two weeks, the SSEA3+/ABCG2+ ES cell population undergoes apoptosis or differentiation, thus exhibiting an altruistic behavior i.e. enhancing group fitness by sacrificing self-fitness (26) . In this preliminary study, we have demonstrated an ASC based innate defense response against infection with the mouse corona virus; MHV-1. The recovered lung CD271+MSCs of MHV-1 infected mice exhibited the ASC phenotype, as shown by their expansion, and expression of genes associated with the HIF-2alpha stemness pathway, followed by the activation of p53 and its downstream genes including p21 and p53 up-regulated modulator of apoptosis (PUMA) on day-20. The activation of genes involved in p53 mediated apoptosis/differentiation was associated with the decrease in lung CD271+MSCs, suggesting that the cells might undergo apoptosis or differentiation, an important phenotypic characteristic of 18 ASCs and ASC based defense mechanism. Notably, further support was obtained for ASC reprogramming in vitro by studying the cytoprotective activity of these ASCs in MHV-1 mediated toxicity of lung alveolar epithelial cells. Thus, the conditioned media of the CD271+MSCs recovered from the MHV-1 infected mouse lung exhibited a direct anti-viral and cytoprotective property on MHV-1 infected type II alveolar epithelial (ATII) cells. Hence, we have identified a unique anti-viral defense system mediated by the innate ASCs. We suggest that ASC defense system may be harnessed to develop novel therapeutic strategies against COVID19.

Furthermore, our results indicate that Mtb infection may boost the MSC mediated ASC defense against MHV-1. Previously, we reported that post-therapy, CD271+BM-MSCs exhibited an enhanced hypoxic phenotype of low CD146 and high HIF-1alpha (18) , which could modify the stemness state to an altruistic stemness state. We hypothesized that infection and inflammation may activate dMtb intracellular to stem cells by activating ASC based defense mechanism (18).

Following MHV-1 infection, the non-replicating dormant m18b-harboring CD271+MSCs underwent ASC reprogramming, and permitted m18b replication. There was also a potential transfer of the pathogen to the extracellular space. However, the detailed mechanism of Mtb reactivation needs further investigation. Here, we speculate that MHV-1 infection inducing inflammation might trigger the mobilization of dMtb harboring MSCs from BM to lung and cause rapid Mtb reactivation in lung, because; (i) studies showed that stem cells mobilize to the area of infection (20) (ii) after 6 months of streptomycin starvation, a few Mtb was found in mice lung CD271+MSCs, whereas a greater number of Mtb were inside BM-CD271+MSCs (17) . The remarkable and significant finding at this moment of COVID19 pandemic is that the Mtb reactivation was associated with significant boosting of the ASC mediated anti-viral activity. 19 Lancet has recently reported that most of the death related to COVID19 is due to acute respiratory distress syndrome (ARDS), which is characterized by cytokine storm. This will mediate a severe attack by the immune system, as seen in cases of SARS-CoV-1 and MERS-CoV infection, leading to the death of the individual (39) . Mesenchymal stem cells (MSCs) are immunosuppressive and they release various immune modulators like nitric oxide (NO), prostaglandin (PGE2), interleukin (IL)-6 and IL-10, which can modulate the innate and adaptive immune response (35) . We speculate that MSC to ASC reprogramming may further increase the secretion of these immunosuppressive cytokines, thus potentially contributing to the reduction of the cytokine storm in COVID19 subjects treated with MSC therapy. BCG vaccine has been proposed to work against COVID19 infection, although the mechanism is not yet known. It is possible that BCG may remain dormant in the lungs, which then reprogram the MSCs to ASCs following COVID19 infection and thus, could exhibit antiviral defense against the virus. MSCs were already shown to exhibit antiviral activity via extracellular vesicles carrying microRNA (40) (41) (42) and human cathelicidin hCAP-18/ LL-3 (43) against influenza, hepatitis C and pneumonia respectively. We also have previously used BCG-MSC interaction to target cancer stem cell (CSCs) (44) . We speculate that the immunosuppressive property of MSCs could help in neutralizing the severe cytokine storm caused by COVID-19. In SARS-CoV2 MHV-1 infection model and immune response, the role of trained immunity has not been evaluated. The trained immunity constitutes innate immune memory where hematopoietic cells may undergo cell intrinsic changes including metabolic and epigenetic modifications to remember pathogenic insult (45) (46) (47) (48) (49) (50) . Trained immunity of MSCs has not yet been studied.

Whether our findings of ASC mediated innate immunity may include a trained immune component requires further investigation. Such a possibility may provide explanation of BCGmediated trained immunity against viral infection (51) (52) . Thus, our model of Mtb and MHV-1 infection in mice to study the putative ASC defense may be a useful model to study potential MSC based trained immunity against corona virus, specifically SARS-COV-2.

In summary, we found that MHV-1 infection induces dMtb loaded MSCs to reprogram to ASCs, thus activating the ASC defense mechanism and diminishing the MHV-1 infection. Knowledge of immunity to SARS-CoV2 is still at a preliminary stage. Thus, our study may help in understanding how MSCs inducing ASC defense mechanism will help in combating the viral load in the host; thereby helping in developing a possible cure for COVID-19.

The Impact of Influenza and Tuberculosis Interaction on Mortality Among Individuals Aged >/=15 Years Hospitalized With Severe Respiratory Illness in South Africa

The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918-19

Influenza and tuberculosis co-infection: A systematic review. Influenza Other Respir Viruses

Severe acute respiratory syndrome and pulmonary tuberculosis

Middle East Respiratory Syndrome Coronavirus and Pulmonary Tuberculosis Coinfection: Implications for Infection Control

Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway

The influence of 23 influenza virus infections on the development of tuberculosis

Tuberculosis as a Risk Factor for 1918 Influenza Pandemic Outcomes

Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa

Paul Nunn (Coordinator) and Dennis Falzon (Medical Officer), Stop TB Department, World Health Organisation

Pandemic Influenza (H1N1) and Mycobacterium tuberculosis Co-infection

THE ENHANCING EFFECT OF CONCURRENT INFECTION WITH PNEUMOTROPIC VIRUSES ON PULMONARY TUBERCULOSIS IN MICE

Interactions between T cells responding to concurrent mycobacterial and influenza infections

Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections

Inflammation in tuberculosis: interactions, imbalances and interventions

Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment

CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis

Preclinical and Clinical Evidence of Mycobacterium tuberculosis Persistence in the Hypoxic Niche of Bone Marrow Mesenchymal Stem Cells after Therapy

Human bone marrow mesenchymal stem cells in vivo

Tracking inflammation-induced mobilization of mesenchymal stem cells

Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice

T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts

Tolllike receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice

Protective and pathologic roles of the immune response to mouse hepatitis virus type 1: implications for severe acute respiratory syndrome

Differentiated phenotypes of primary murine alveolar epithelial cells and their susceptibility to infection by respiratory viruses

HIF-2alpha suppresses p53 to enhance the stemness and regenerative potential of human embryonic stem cells

Reactivation of latent tuberculosis: variations on the Cornell murine model

Coronaviruses: propagation, quantification, storage, and construction of recombinant mouse hepatitis virus

Oral cancer stem cells modulate Fusobacterium nucleatumto acquire the capability to induce tumor stemness switch

the American Association for Cancer Research Annual Meeting

Unique model of dormant infection for tuberculosis vaccine development

MYC Regulates the HIF2alpha Stemness Pathway via Nanog and Sox2 to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells

Canalization of Development and the Inheritance of Aquired Characters

Altruistic stem cells and cancer stem cells

Migratory cancer side population cells induces stem cell altruism in bone marrow mesenchymal stem cells to resist therapy, and enhance tumorigenic potential of non-tumorigenic cells

In vitro Culture of Naive Human Bone Marrow Mesenchymal Stem Cells: A Stemness Based Approach

Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

Could BCG be used to protect against COVID-19?

Bacterial charity work leads to population-wide resistance

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection

Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model

Mesenchymal stem cells detect and defend against gammaherpesvirus infection via the cGAS-STING pathway

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

Targeting oral cancer stem cells in the hypoxic niche by BCG infected mesenchymal stem cells

Immune Training Unlocks Innate Potential

Trained immunity: a memory for innate host defense

Innate immune memory: An evolutionary perspective

Training innate immunity: the changing concept of immunological memory in innate host defence

Metabolic Induction of Trained Immunity through the Mevalonate Pathway

Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming

Mtb in the lungs of a mouse model of stem cell mediated Mtb dormancy. A. Schematic of producing the dormant Mtb (dMtb) mouse model, and the experimental design for dMtb reactivation

Mtb-CFUs in the lungs of mice from day-30 post MHV-1 infection, or day-30 post treatment with dexamethasone or aminoguanidine. All the mice were treated with daily streptomycin sixdays per week for three weeks. **P< 0.001, ***P<0.0001, Student's t-test

MHV-1 alone = healthy adult mice infected with MHV-1 only. The dMtb alone = mice harboring dormant Mtb (dMtb) intracellular to lung and BM CD271+ MSCs. dMtbMHV-1 = dMtb harboring mice